Table 4.
Safety Analysis of 59 MM Patients
| Any Grade | Grade 3/4 | |
|---|---|---|
| Hematological adverse events | ||
| Anemia | 8 (13.6) | 1 (1.7) |
| Thrombocytopenia | 6 (10.2) | 2 (3.4) |
| Neutropenia | 5 (8.5) | – |
| Nonhematological adverse events | ||
| PNa (32 patients) | 8 (25.0) | 1(3.1) |
| Diarrhea | 8 (13.6) | 1 (1.7) |
| Infection | 5 (8.5) | – |
| Cardiac events | 4 (6.8) | 2 (3.4) |
| Liver dysfunction | 2 (3.4) | – |
| Nausea and vomit | 2 (3.4) | – |
| Skin rash | 2 (3.4) | 1 (1.7) |
| Fatigue | 2 (3.4) | – |
| Edema | 1 (1.7) | – |
| Cerebropathy | 1 (1.7) | 1 (1.7) |
| Constipation | 1 (1.7) | – |
Note: aBecause it is hard to attribute PN to ixazomib or prior-bortezomib treatment, the 27 bortezomib PN intolerant patients in continuing therapy group were excluded here, and analyzed separately in the discussion part.
Abbreviation: PN, peripheral neuritis.